{"id":48704,"date":"2025-11-20T15:55:48","date_gmt":"2025-11-20T07:55:48","guid":{"rendered":"https:\/\/flcube.com\/?p=48704"},"modified":"2025-11-20T15:55:49","modified_gmt":"2025-11-20T07:55:49","slug":"kelun-biotechs-trastuzumab-botidotin-her2-adc-launches-in-china-after-phase-3-win-vs-t-dm1","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48704","title":{"rendered":"Kelun-Biotech&#8217;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1"},"content":{"rendered":"\n<p><strong>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>) announced the official China launch of <strong>trastuzumab botidotin<\/strong>, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on <strong>17\u202fOct\u202f2025<\/strong>. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-launch-milestone\">Commercial Launch Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>trastuzumab botidotin (HER2 ADC)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Kelun\u2011Biotech (6990.HK)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>17\u202fOct\u202f2025 (NMPA)<\/td><\/tr><tr><td><strong>Launch Date<\/strong><\/td><td>19\u202fNov\u202f2025 (China market)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>HER2\u2011positive unresectable or metastatic breast cancer (post\u2011trastuzumab + taxane)<\/td><\/tr><tr><td><strong>Competitor Benchmark<\/strong><\/td><td>Head\u2011to\u2011head vs trastuzumab emtansine (T\u2011DM1)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Investigational HER2\u2011targeted ADC developed entirely by Kelun\u2011Biotech<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Delivers cytotoxic payload directly to HER2\u2011overexpressing tumor cells<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> First Chinese\u2011developed HER2 ADC to launch with Phase\u202fIII head\u2011to\u2011head superiority data vs. established standard of care (T\u2011DM1)<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global patents held by Kelun\u2011Biotech; no disclosed out\u2011licensing agreements<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-kl166-\u2172-06-phase-3-trial\">Clinical Evidence \u2013 KL166-\u2162-06 Phase 3 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Trastuzumab Botidotin<\/th><th>T\u2011DM1 Control<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Median PFS<\/strong><\/td><td><strong>11.1\u202fmonths<\/strong><\/td><td>4.4\u202fmonths<\/td><td><strong>+6.7\u202fmonths<\/strong><\/td><\/tr><tr><td><strong>PFS HR<\/strong><\/td><td><strong>0.39<\/strong> (61% risk reduction)<\/td><td>\u2013<\/td><td><strong>p&lt;0.0001<\/strong><\/td><\/tr><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>76.9%<\/strong><\/td><td>\u2013<\/td><td>Superior vs historical T\u2011DM1 data (~40\u201145%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The trial enrolled HER2\u2011positive unresectable\/metastatic breast cancer patients who progressed after prior trastuzumab and taxane\u2011based therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China HER2+ Breast Cancer Market:<\/strong> ~60,000 new cases annually; ~30% develop metastatic disease eligible for ADC therapy<\/li>\n\n\n\n<li><strong>T\u2011DM1 Current Share:<\/strong> T\u2011DM1 (Kadcyla) holds ~40% of second\u2011line HER2+ metastatic market in China, with estimated 2025 sales of <strong>\u00a52.5\u202fbillion<\/strong> (~US$340\u202fmillion)<\/li>\n\n\n\n<li><strong>Pricing Strategy:<\/strong> Kelun\u2011Biotech is expected to price trastuzumab botidotin at a <strong>15\u201120% discount<\/strong> to T\u2011DM1, capturing cost\u2011sensitive hospitals while leveraging superior efficacy data<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project trastuzumab botidotin could achieve <strong>\u00a51.2\u20111.8\u202fbillion<\/strong> (~US$165\u2011245\u202fmillion) in China peak sales by 2030, assuming 25\u201130% market share capture in second\u2011line HER2+ metastatic setting<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Faces competition from <strong>AstraZeneca\/Daiichi\u2019s ENHERTU<\/strong> (HER2 ADC) and <strong>Jiangsu Alphamab\u2019s ARX788<\/strong>, but head\u2011to\u2011head T\u2011DM1 data provides strong differentiation for prescribers<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Kelun\u2011Biotech plans to submit for <strong>National Reimbursement Drug List (NRDL)<\/strong> inclusion in 2026; global expansion discussions are underway with potential partners for US\/EU markets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding trastuzumab botidotin\u2019s commercial launch performance, market penetration, and revenue projections. Actual results may differ materially due to risks including market acceptance, reimbursement negotiations, competitive responses, and regulatory changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48705,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,83,971,371,40],"class_list":["post-48704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-her2","tag-hkg-6990","tag-kelun-pharmaceutical","tag-market-launch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech&#039;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48704\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech&#039;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48704\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T07:55:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T07:55:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech&#8217;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1\",\"datePublished\":\"2025-11-20T07:55:48+00:00\",\"dateModified\":\"2025-11-20T07:55:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2003.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"HER2\",\"HKG: 6990\",\"Kelun Pharmaceutical\",\"Market launch\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48704#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48704\",\"name\":\"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2003.webp\",\"datePublished\":\"2025-11-20T07:55:48+00:00\",\"dateModified\":\"2025-11-20T07:55:49+00:00\",\"description\":\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48704\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2003.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48704#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech&#8217;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1 - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48704","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1","og_description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.","og_url":"https:\/\/flcube.com\/?p=48704","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-20T07:55:48+00:00","article_modified_time":"2025-11-20T07:55:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48704#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48704"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech&#8217;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1","datePublished":"2025-11-20T07:55:48+00:00","dateModified":"2025-11-20T07:55:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48704"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48704#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","keywords":["ADC \/ XDC","HER2","HKG: 6990","Kelun Pharmaceutical","Market launch"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48704#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48704","url":"https:\/\/flcube.com\/?p=48704","name":"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48704#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48704#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","datePublished":"2025-11-20T07:55:48+00:00","dateModified":"2025-11-20T07:55:49+00:00","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin, its innovative HER2\u2011targeted antibody\u2011drug conjugate (ADC), following NMPA approval on 17\u202fOct\u202f2025. The drug is positioned to challenge T\u2011DM1 in HER2\u2011positive metastatic breast cancer after demonstrating superior PFS in a head\u2011to\u2011head Phase\u202fIII trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48704#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48704"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48704#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","width":1080,"height":608,"caption":"Kelun-Biotech's Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48704#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech&#8217;s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48704"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48704\/revisions"}],"predecessor-version":[{"id":48706,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48704\/revisions\/48706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48705"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}